文献速递淋巴瘤造血干细胞移植与细胞治疗

实体器官移植后儿童伯基特淋巴瘤:儿童移植后淋巴增殖性疾病协作组的治疗与结局

Burkitt lymphoma after solid-organ transplant: Treatment and outcomes in the paediatric PTLD collaborative.
PubMed 文献 · Br J Haematol · 2022-12-01

该研究评估美国14家儿童医学中心诊断的35例儿童实体器官移植后伯基特淋巴瘤(PSOT-BL)患者。移植中位年龄2.0岁,诊断中位年龄8.0岁,移植至诊断中位间隔4.0年。3年无事件生存率和总生存率分别为66.2%和88.0%,无移植物丢失或治疗相关死亡。

要点

  • 儿童PSOT-BL多发生于移植后晚期(≥2年),中位间隔4.0年。
  • 最常用方案为强效BL特异性FAB/LMB方案(37.1%)和低强度CPR方案(34.3%)。
  • 3年无事件生存率66.2%,总生存率88.0%,无移植物丢失或治疗相关死亡。

核心结论

  • 接受BL特异性强效方案的PSOT-BL患者结局与已报道的免疫功能正常儿童BL结局相当。
  • 多机构协作可行,为前瞻性数据收集以确定PSOT-BL最佳治疗方案提供了基础。

研究设计与样本

  • 研究纳入美国14家儿童医学中心诊断的35例儿童实体器官移植后伯基特淋巴瘤(PSOT-BL)患者。
  • 移植中位年龄2.0岁(范围0.1-14),PSOT-BL诊断中位年龄8.0岁(范围1-17)。
  • 除1例外均为晚发型PSOT-BL(移植后≥2年),移植至诊断中位间隔4.0年(范围0.4-12)。
  • 移植器官以心脏(n=18 [51.4%])和肝脏(n=13 [37.1%])最常见。
  • 中位随访6.7年(范围0.5-17)。

主要发现

  • 无患者出现移植物丢失或治疗相关死亡。
  • 3年无事件生存率为66.2%,3年总生存率为88.0%。
  • 治疗方案多样,以强效BL特异性FAB/LMB方案(n=13 [37.1%])和低强度环磷酰胺+泼尼松+利妥昔单抗(CPR)方案(n=12 [34.3%])为主。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Burkitt lymphoma arising in paediatric post-solid-organ transplantation-Burkitt lymphoma (PSOT-BL) is a clinically aggressive malignancy and a rare form of post-transplant lymphoproliferative disorder (PTLD). We evaluated 35 patients diagnosed with PSOT-BL at 14 paediatric medical centres in the United States. Median age at organ transplantation was 2.0 years (range: 0.1-14) and age at PSOT-BL diagnosis was 8.0 years (range: 1-17). All but one patient had late onset of PSOT-BL (≥2 years post-transplant), with a median interval from transplant to PSOT-BL diagnosis of 4.0 years (range: 0.4-12). Heart (n = 18 [51.4%]) and liver (n = 13 [37.1%]) were the most frequently transplanted organs. No patients had loss of graft or treatment-related mortality. A variety of treatment regimens were used, led by intensive Burkitt lymphoma-specific French-American-British/Lymphomes Malins B (FAB/LMB), n = 13 (37.1%), and a low-intensity regimen consisting of cyclophosphamide, prednisone and rituximab (CPR) n = 12 (34.3%). Median follow-up was 6.7 years (range: 0.5-17). Three-year event-free and overall survival were 66.2% and 88.0%, respectively. Outcomes of PSOT-BL patients receiving BL-specific intensive regimens are comparable to reported BL outcomes in immunocompetent children. Multi-institutional collaboration is feasible and provides the basis of prospective data collection to determine the optimal treatment regimen for PSOT-BL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Afify Z, Orjuela-Grimm M, Smith CM, et al. Burkitt lymphoma after solid-organ transplant: Treatment and outcomes in the paediatric PTLD collaborative. Br J Haematol. 2022. PMID: 36454546. doi:10.1111/bjh.18498

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。